

10th February 2026

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
--	--

Ref.: Clarification on News Item Appearing in Economic Times- Intimation under Regulation 30(11) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs/Madam,

This is with reference to a news article published in the print edition of *The Economic Times* dated February 10, 2026 (appearing on pages 1 and 9) as well as on ET Online, titled ***“Ajanta may raise Rs 2,000 crore to buy Restaurant Brands Asia.”***

In this connection, we draw your attention to the clarification submitted by the Company to the Stock Exchanges on January 20, 2026, pursuant to a similar news article published in various media outlets.

We wish to clarify that the article published today in *The Economic Times* contains an incorrect and inadvertent reference stating that *“The transaction would mark the drugmaker’s diversification into the fast-growing quick service restaurant sector.”*

In this regard, we clarify that a section of the promoter group of Ajanta which is managing and controlling Lenexis Foodworks Pvt. Ltd. is independently in the process of acquiring Restaurant Brands Asia. Ajanta Pharma Limited and its Management are not parties to, and are in no manner involved in, any transaction referred to in the said news article.

Accordingly, the reference to Ajanta Pharma Limited in the said article is factually incorrect. The Company hereby denies the rumours and speculation circulating in this regard.

We request you to take the above clarification on record and disseminate it to all concerned.

Thanking you,

Yours faithfully,

Gaurang Shah
Sr. VP – Legal & Company Secretary